Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Amro Aboukameel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-9912-2887; OpenAlex author ID A5038465132. Sources: OpenAlex.

Their work

Papers
28 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
40
Papers, trials and grants by year

2011: 1 paper · 2012: 2 papers · 2013: 2 papers · 2014: 5 papers · 2015: none · 2016: none · 2017: 2 papers · 2018: 1 paper · 2019: 2 papers · 2020: 2 papers · 2021: none · 2022: 3 papers · 2023: 3 papers · 2024: 1 paper · 2025: 3 papers · 2026: 1 paper

Papers 28

  1. XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2026.218804↗
  2. Pharmacological advances in cannabinoid-based therapies for pancreatic cancer: preclinical efficacy of CCL-106 and its epimers. Co-author DOI 10.1016/j.esmogo.2025.100211↗
  3. Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2025.11.21.689857↗
  4. PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic Cancer Co-author DOI 10.64898/2025.12.06.692635↗
  5. RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth. First author DOI 10.1016/j.canlet.2024.217275↗
  6. Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model. Co-author DOI 10.1002/ctm2.1513↗
  7. Targeting Cellular Metabolism With CPI-613 Sensitizes Pancreatic Cancer Cells to Radiation Therapy. Co-author DOI 10.1016/j.adro.2022.101122↗
  8. Regulator of Chromosome Condensation (RCC1) a novel therapeutic target in pancreatic ductal adenocarcinoma drives tumor progression via the c-Myc-RCC1-Ran axis First author DOI 10.1101/2023.12.18.572102↗
  9. Connecting the Human Microbiome and Pancreatic Cancer. Co-author DOI 10.1007/s10555-022-10022-w↗
  10. Correction to: Connecting the human microbiome and pancreatic cancer. Co-author DOI 10.1007/s10555-022-10037-3↗
  11. Molecular profiling of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in cellular and LSL-Kras G12D/+; Trp53 fl/+; Pdx1-Cre (KPC) pancreatic cancer … First author DOI 10.1101/2022.03.08.481108↗
  12. Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-19-1728↗
  13. Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferation and Patient-Derived Tumor Growth. Co-author DOI 10.3390/cancers12030750↗
  14. Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarc… Co-author DOI 10.1080/21541248.2017.1329694↗
  15. DNA-Methylation-Caused Downregulation of miR-30 Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcin… Co-author DOI 10.3390/cancers11081101↗
  16. Retraction notice to "Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells" [Cancer Lett. 31… Co-author DOI 10.1016/j.canlet.2017.11.030↗
  17. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1535-7163.mct-16-0205↗
  18. Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration. Co-author DOI 10.18632/oncotarget.19285↗
  19. Deregulation of miR-146a expression in a mouse model of pancreatic cancer affecting EGFR signaling. Co-author DOI 10.1016/j.canlet.2014.05.013↗
  20. Pancreatic cancer stem-like cells display aggressive behavior mediated via activation of FoxQ1. Co-author DOI 10.1074/jbc.m113.532887↗
  21. Differentially expressed miRNAs in cancer-stem-like cells: markers for tumor cell aggressiveness of pancreatic cancer. Co-author DOI 10.1089/scd.2013.0551↗
  22. A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo. Co-author DOI 10.1158/1535-7163.mct-12-0767↗
  23. Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer. Co-author DOI 10.18632/oncotarget.1813↗
  24. Synthesis, characterization and anti-tumor activity of novel thymoquinone analogs against pancreatic cancer. Co-author DOI 10.1016/j.bmcl.2013.03.003↗
  25. Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. First author DOI 10.1053/j.gastro.2012.10.036↗
  26. RETRACTED: Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells. Co-author DOI 10.1016/j.canlet.2012.01.013↗
  27. Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. Co-author DOI 10.1371/journal.pone.0050165↗
  28. Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0017850↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Asfar Sohail Azmi · 23 shared papers, 2012–2026 · strength 2.57
  2. Husain Yar Khan · 13 shared papers, 2020–2026 · strength 2.00
  3. Sahar F. Bannoura · 10 shared papers, 2022–2026 · strength 1.59
  4. Philip A. Philip · 15 shared papers, 2011–2025 · strength 1.42
  5. Md. Hafiz Uddin · 9 shared papers, 2022–2026 · strength 1.42
  6. Ramzi M. Mohammad · 14 shared papers, 2013–2026 · strength 1.41
  7. Mohammed Najeeb Al Hallak · 8 shared papers, 2020–2026 · strength 1.23
  8. Yiwei Li · 10 shared papers, 2012–2023 · strength 1.05
  9. Bassel F. El‐Rayes · 6 shared papers, 2022–2026 · strength 0.99
  10. Bin Bao · 11 shared papers, 2011–2026 · strength 0.89
  11. Boris Pasche · 5 shared papers, 2023–2026 · strength 0.88
  12. Muhammad Wasif Saif · 4 shared papers, 2024–2026 · strength 0.72
  13. Eliza Wright Beal · 4 shared papers, 2023–2026 · strength 0.70
  14. Anthony Frank Shields · 4 shared papers, 2022–2026 · strength 0.64
  15. Steve H. Kim · 5 shared papers, 2020–2025 · strength 0.63
  16. Rachel E. Sexton · 4 shared papers, 2020–2022 · strength 0.50
  17. Irfana Muqbil · 5 shared papers, 2017–2020 · strength 0.44
  18. Fazlul H. Sarkar · 9 shared papers, 2011–2018 · strength 0.38
  19. P. A. Philip · 2 shared papers, 2025–2026 · strength 0.37
  20. Azeddine Atfi · 2 shared papers, 2025–2026 · strength 0.37
  21. Mandana Kamgar · 3 shared papers, 2020–2023 · strength 0.35
  22. Kay‐Uwe Wagner · 2 shared papers, 2023–2024 · strength 0.33
  23. Shadan S. Ali · 7 shared papers, 2011–2018 · strength 0.30
  24. Bayan A. Al-Share · 2 shared papers, 2022 · strength 0.27
  25. K.P. Ray · 1 shared paper, 2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.